# OnCo record ever-supreme-bio-technology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/ever-supreme-bio-technology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "ever-supreme-bio-technology" ;
  schema:name "Ever Supreme Bio Technology"@en ;
  schema:alternateName "Ever Supreme Bio Technology Co., Ltd."@en, "Ever-Supreme"@en, "Ever Supreme Bio Technology, Co. Ltd."@en ;
  schema:description "Ever Supreme Bio Technology is a Taiwanese company developing immune cell and stem cell medicines. Its cancer medicine, CAR001, uses donor immune cells built to find tumours, and the FDA gave it orphan drug status for malignant glioma in 2026."@en ;
  schema:url <https://onco.cc/companies/ever-supreme-bio-technology/>, <https://en.ever-supreme.com.tw/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://en.ever-supreme.com.tw/>, <https://en.ever-supreme.com.tw/news_detail/39>, <https://en.ever-supreme.com.tw/news_detail/41>, <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1176726> ;
  schema:addressCountry "TW" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/gamma-delta-t-cell-therapy/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/allogeneic-cell-therapy/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/car001/> ;
  onco:trials <https://onco.cc/trials/nct06150885/> .